|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 452.04 USD | +1.37% |
|
-0.76% | +12.25% |
| Capitalization | 115B 97.71B 91.27B 85.87B 158B 10,388B 173B 1,065B 413B 4,897B 430B 421B 17,865B | P/E ratio 2025 * |
29.1x | P/E ratio 2026 * | 25.8x |
|---|---|---|---|---|---|
| Enterprise value | 106B 90B 84.07B 79.1B 146B 9,569B 159B 981B 381B 4,511B 396B 388B 16,457B | EV / Sales 2025 * |
8.81x | EV / Sales 2026 * | 7.73x |
| Free-Float |
99.04% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +1.37% | ||
| 1 week | -0.76% | ||
| Current month | +4.25% | ||
| 1 month | +4.03% | ||
| 3 months | +14.58% | ||
| 6 months | -0.75% | ||
| Current year | +12.25% |
| 1 week | 433.81 |  | 457.17 |
| 1 month | 418.53 | | 463.85 |
| Current year | 362.5 | | 519.68 |
| 1 year | 362.5 | | 519.68 |
| 3 years | 282.21 | | 519.88 |
| 5 years | 176.36 | | 519.88 |
| 10 years | 71.46 | | 519.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 31/03/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 09/04/2019 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 65 | 31/12/1997 |
Jeffrey Leiden
CHM | Chairman | 69 | 30/04/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 56 | 17/06/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.37% | -0.76% | -2.52% | +47.20% | 115B | |
| +1.80% | +1.70% | +30.21% | +186.49% | 920B | |
| +0.75% | +4.78% | +44.31% | +18.06% | 510B | |
| -0.29% | -1.22% | +28.81% | +35.52% | 395B | |
| -0.35% | +1.90% | +25.12% | +3.11% | 340B | |
| -1.12% | -1.09% | +28.43% | +18.70% | 278B | |
| -0.45% | -1.48% | +20.24% | +24.41% | 254B | |
| +1.30% | +0.58% | -1.67% | -9.57% | 249B | |
| +0.45% | +3.73% | -57.41% | -30.85% | 224B | |
| +0.11% | -3.68% | +17.41% | +16.70% | 171B | |
| Average | +0.36% | +0.45% | +13.29% | +30.98% | 345.67B | |
| Weighted average by Cap. | +0.57% | +1.08% | +21.05% | +59.67% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 11.99B 10.22B 9.54B 8.98B 16.53B 1,086B 18.06B 111B 43.21B 512B 45.01B 44.06B 1,868B | 13.05B 11.12B 10.38B 9.77B 17.99B 1,182B 19.65B 121B 47.01B 557B 48.96B 47.93B 2,032B |
| Net income | 3.99B 3.4B 3.17B 2.98B 5.49B 361B 6B 37.03B 14.36B 170B 14.96B 14.64B 621B | 4.5B 3.83B 3.58B 3.37B 6.2B 408B 6.78B 41.81B 16.22B 192B 16.89B 16.53B 701B |
| Net Debt | -9.04B -7.7B -7.19B -6.77B -12.46B -819B -13.61B -83.97B -32.57B -386B -33.92B -33.21B -1,408B | -13.85B -11.8B -11.02B -10.37B -19.09B -1,254B -20.86B -129B -49.9B -591B -51.97B -50.87B -2,157B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 452.04 $ | +1.37% | 1,621,663 |
| 11/12/25 | 445.93 $ | +0.29% | 1,178,366 |
| 10/12/25 | 444.64 $ | +1.75% | 999,755 |
| 09/12/25 | 437.01 $ | -1.14% | 989,612 |
| 08/12/25 | 442.04 $ | -2.95% | 1,504,581 |
Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition